CDSCO directs enforcement against unauthorised GLP-1 drug promotion and distribution
Pharmacies and GLP-1 marketers face tighter enforcement on channels and promotion
CDSCO
·
Change
CDSCO directed State and Union Territory Drug Controllers to strengthen enforcement against unauthorised promotion, distribution and dispensing of GLP-1 based weight-loss drugs.
Why it matters
The directive turns GLP-1 supply-chain and promotion controls into an active enforcement priority. Pharmacies, wholesalers, online sellers, wellness clinics and marketers must keep GLP-1 distribution and advertising within approved channels, indications and labelling conditions.
Implications
- — Online pharmacies, wholesalers and retail outlets handling GLP-1 based weight-loss drugs must keep sale and dispensing within authorised channels and approved label conditions.
- — Wellness and slimming clinics promoting or facilitating GLP-1 use must remove non-compliant advertising and surrogate promotion from digital, social-media, print and outdoor channels.
- — Manufacturers, importers and marketers of GLP-1 based drugs must align distribution and promotional activity with approved indications and labelling because State/UT drug controllers have been asked to initiate enforcement action for violations.
Full decision brief
See the decision layer
Use 1 free preview to unlock implications, who’s affected, what to watch, and Clarify for this brief.
2 free previews left this month · Resets 1 Jun
Source